Brief: Simcere Pharmaceutical Posts HY Profit Attributable RMB2,275 Mln
21/08/2023 14:21
Aug 21 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* HY PROFIT ATTRIBUTABLE RMB2,275 MILLION VERSUS RMB64
MILLION
* HY REVENUE RMB3,379 MILLION, UP 25.2%
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660